AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
RGC Resources' 15min chart shows KDJ Death Cross, Bearish Marubozu.
ByAinvest
Tuesday, Aug 5, 2025 3:49 pm ET1min read
Amarin's 15-minute chart has triggered a narrowing of Bollinger Bands, and a KDJ Death Cross occurred on August 5th, 2025, at 15:45. This indicates a decline in the magnitude of stock price fluctuations and a shift in momentum towards the downside, with a potential for further price decrease.
Amarin Corporation (AMRN) reported its second-quarter (Q2) 2025 earnings, which exceeded expectations and sparked a 2.2% stock price increase on July 30. The company reported a loss of 3 cents per share, significantly narrower than the Zacks Consensus Estimate of a loss of 66 cents per share [1]. Adjusted earnings per share (EPS) were 4 cents, up from 1 cent in the year-ago quarter. Total revenues reached $72.7 million, an 8% increase year-over-year (YoY), driven by higher licensing and royalty revenues [1].Vascepa, Amarin's sole marketed drug, generated $46.6 million in net product revenues, down 2% YoY. U.S. product revenues from Vascepa declined 17% due to rising generic competition, while European revenues surged 85%. Licensing and royalty revenues increased 31% to $26.1 million, driven by an upfront payment under a new European licensing agreement with Recordati [1].
Amarin's stock has rallied 54.3% so far this year compared to the industry's 1% rise. However, recent technical indicators suggest a potential downside. Amarin's 15-minute chart has triggered a narrowing of Bollinger Bands, indicating a decline in price fluctuation magnitude. Additionally, a KDJ Death Cross occurred on August 5, 2025, at 15:45, signaling a shift in momentum towards the downside [2].
Despite the positive earnings report, investors should remain cautious due to these technical signals. Amarin's partnership with Recordati and its restructuring efforts aim to boost growth and cash position, but the potential downside risk highlighted by the technical indicators should not be overlooked.
References:
[1] The Globe and Mail. "Amarin's Q2 Earnings in Detail." https://www.theglobeandmail.com/investing/markets/stocks/CRMD-Q/pressreleases/33784729/amarin-s-q2-earnings-revenues-trump-estimates-stock-rises/
[2] Zacks Investment Research. "Amarin Corporation PLC: Free Stock Analysis Report." https://www.zacks.com/stock/quote/AMRN
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet